While brand-based and generic TLDs are fascinating in terms of their potential to shake-up domain name giants and revolutionize online branding, only a handful of them will possess staying power.
With billions of dollars at stake and neither company certain how it might fare in court, a brand-name manufacturer might prefer to pay its potential competitor substantial compensation to delay its generic drug and the generic maker might welcome a hefty payoff rather than face the uncertainties of litigation and marketing.
Kogan compared Zetia to the company's allergy blockbuster, Claritin, which will soon either face generic competition or be sold over the counter, dulling its sales potential.